Popular terms

[SEARCH]

Immune Diseases topics
Immune Diseases
Autoimmune
Immune Disease
Autoimmune Disease
Autoimmune Diseases
Immune Disorder
Rheumatoid Arthritis
Antibodies
Antagonist
Nucleotide
Proliferative
Infectious
Infectious Disease
Infectious Diseases
Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Diseases patents



      
           
This page is updated frequently with new Immune Diseases-related patent applications. Subscribe to the Immune Diseases RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Diseases RSS RSS



Date/App# patent app List of recent Immune Diseases-related patents
08/27/15
20150241448 
 Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders patent thumbnailLanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders
The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component c-like (lancl) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs.
Virginia Tech Intellectual Properties, Inc.


08/27/15
20150239957 
 Ig-pconsensus gene vaccination protects from antibody-dependent immune pathology in autoimmune disease patent thumbnailIg-pconsensus gene vaccination protects from antibody-dependent immune pathology in autoimmune disease
The disclosure provides a fusion polypeptide and compositions useful for treating autoimmune diseases and disorders. The fusion polypeptide comprises a first domain comprising a self antigen which is a conserved sequence found in t cell determinants in the fr1/cdr1 region of vh of human and murine igg antibodies, particularly seq id no:2 or an antigenic fragment thereof; and a second domain comprising a heterologous polypeptide or small molecule..
Università Degli Studi Di Genova


08/27/15
20150239897 
 Pyrrolopyrimidine compounds as kinase inhibitors patent thumbnailPyrrolopyrimidine compounds as kinase inhibitors
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.


08/27/15
20150238548 
 Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases patent thumbnailLactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases
The present invention is related to a lactobacillus strain, composition and use thereof for treating autoimmune disease and related complications. The composition comprises at least one isolate of lactobacillus paracasei strain gmnl-32, l.
Genmont Biotech Incorporation


08/27/15
20150238493 
 Medicament for treating peripheral neuropathies patent thumbnailMedicament for treating peripheral neuropathies
The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (hsv), and then administering to the human the compound anti-hsv agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (neurodermatitis, prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, parkinson's disease, anemia, cytopenia those among the diagnostic criteria..

08/27/15
20150238445 
 Composition using metformin for preventing or treating immune diseases including lupus patent thumbnailComposition using metformin for preventing or treating immune diseases including lupus
The present invention relates to a composition for preventing or treating immune diseases through the suppression of b cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of b cell activity which is a cause of disease.
Catholic University Industry Academic Cooperation Foundation


08/20/15
20150231281 
 Inflammation imaging and therapy patent thumbnailInflammation imaging and therapy
An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is lewis a or lewis b or a mimetic thereof, or a pharmaceutically acceptable salt or pegylated form of lewis a or lewis b or its mimetics.
Isis Innovation Limited


08/13/15
20150225398 
 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders patent thumbnailNovel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224199 
 Pharmaceutical compositions for the treatment of inflammatory disorders patent thumbnailPharmaceutical compositions for the treatment of inflammatory disorders
Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224146 
 Cell populations having immunoregulatory activity,  isolation and uses patent thumbnailCell populations having immunoregulatory activity, isolation and uses
The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .
Consejo Superior De Investigaciones Cientificas


08/13/15
20150224141 

Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases


Methods for enhancing the suppressive function of myeloid derived suppressor cells (mdscs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the small compounds are glatiramer acetate and mitogen activated protein (map) kinase inhibitors.
Icahn School Of Medicine At Mount Sinai


08/06/15
20150218260 

Interleukin-2 fusion proteins and uses thereof


The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (il-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant il-2 that exhibit improved properties for use as therapeutic agents, e.g.
Hoffman-la Roche Inc.


08/06/15
20150218239 

Fcrn antagonists and methods of use


Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
The Board Of Regents Of The University Of Texas System


08/06/15
20150216971 

Methods for treating gi syndrome and graft versus host disease


It has been discovered that administering therapeutically effective amounts of an antibiotic that kills gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic t lymphocyte (ctl)-induced killing and/or by damage to endothelial microvasculature, including radiation gi syndrome, cgvhd disease, inflammatory diseases and autoimmune diseases.. .
Sloan Kettering Institute For Cancer Research


08/06/15
20150216908 

Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation


The invention unexpectedly found that an isolated and modified qpsc population has multi-potentiality, including: osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). The qpsc population of the invention features a desirable immunomodulation ability, including inducing, enhancing, or suppressing an immune response and thus has potential value in the prevention and/or treatment of various immune diseases/disorders/conditions.
Steminent Biotherapeutics Inc.


07/30/15
20150210704 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula i: wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


07/30/15
20150210703 

Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases


The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof. The formula i compounds inhibit tyrosine kinase activity of jak3, thereby making them useful for the treatment of inflammatory and autoimmune diseases..
Bristol-myers Squibb Company


07/30/15
20150209288 

Core-shell particle formulation for delivering multiple therapeutic agents


A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, the formulation comprising protein-protein core-shell particle configured to independently release therapeutic agents from the core and the shell.
Amrita Vishwa Vidyapeetham


07/23/15
20150203847 

Chemical modifications of monomers and oligonucleotides with cycloaddition


In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

07/23/15
20150203560 

Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases


The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (ifn) molecule attached to an antibody (ab) which targets an antigen which is differentially expressed or up-regulated on activated t cells as compared to resting t cells, wherein the fusion molecule when contacted to an activated t cell results in induced apoptosis and programmed cell death or impairment of functions of said activated t cell..
Immungene Inc.


07/23/15
20150203455 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein cy, r1, l1, r3, r4, r5, la, and ra are as defined herein. Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons..

07/23/15
20150202318 

Aberrant cell-restricted immunoglobulins provided with a toxic moiety


Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.


07/23/15
20150202285 

Compositions and methods for modulating immune responses


This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the nf-κb signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases..
The University Of Queensland


07/16/15
20150196511 

Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease


The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of il-17 and tnf-a, and promoting or increasing the activity of ifnr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease..
Catholic University Industry Academic Cooperation Foundation


07/09/15
20150191699 

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof


The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
Imstem Biotechnology, Inc.


07/09/15
20150191464 

Heteroaryl substituted nicotinamide compounds


Or salts thereof, wherein: het is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1h-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with ra and rb; and r1 and r2 are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.

07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


07/02/15
20150183775 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


07/02/15
20150182539 

Pregnancy hormone combination for treatment of autoimmune diseases


The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.. .
The Regents Of The University Of California


07/02/15
20150182487 

Composition for preventing and treating inflammatory diseases and immune diseases, containing apo-9`-fucoxanthinone as active ingredient


The present invention relates to a composition for preventing and treating inflammatory diseases and immune diseases, containing a sargassum muticum extract and apo-9′-fucoxanthinone as active ingredients. According to the present invention, the sargassum muticum extract and apo-9′-fucoxanthinone show an excellent inhibiting activity for the generation of il-12, il-6 and tnf-α, which are inflammatory cytokines, in a macrophage and a dendritic cell due to a stimulating factor causing an inflammatory response, remarkably inhibit mapk and ap-1 activity, and inhibit the activity of nlrp3 inflammasome which is known to be involved in the pathogenesis of various immune inflammatory diseases, and thus can be ultimately useful for the development of an agent for treating inflammatory diseases and immune diseases caused by an excessive immune inflammatory response.
Jeju National University Industry Academic Cooperation Foundation


06/25/15
20150175979 

Ptprs and proteoglycans in autoimmune disease


Provided herein, inter alia, are ptprs de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject.
La Jolla Institute For Allergy And Immunology


06/25/15
20150175710 

Alpha-enolase specific antibodies and use in immune diseases


A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology


06/25/15
20150175623 

Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them


Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .

06/25/15
20150174178 

Method and system for prevention and treatment of allergic and inflammatory diseases


A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

06/18/15
20150166658 

Bcr-complex-specific antibodies and methods of using same


This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


06/18/15
20150165006 

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen


The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Cure Gmbh


06/18/15
20150164948 

Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases


This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services


06/18/15
20150164902 

Concentrated methotrexate solutions


Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh


06/11/15
20150158912 

Treatment of il-17 mediated disease by blocking sefir-sefir interactions


A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.
The Cleveland Clinic Foundation


06/11/15
20150158871 

Crystalline forms of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics, Inc.


06/11/15
20150158865 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics, Inc.


06/04/15
20150152097 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


06/04/15
20150150951 

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity


The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.

06/04/15
20150150912 

Ceacam1 mediated protective immunity


The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..

05/28/15
20150148361 

Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
Janssen Pharmaceutica Nv


05/21/15
20150141523 

Compounds for use in the treatment of autoimmune inflammatory disease


And salts thereof is useful in the prophylaxis or treatment of inflammatory bowel disease or other inflammatory autoimmune diseases with similar aetiology involving t-cell proliferation or or function.. .

05/21/15
20150141397 

Substituted anilines as ccr(4) antagonists


Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.


05/21/15
20150141328 

Stimulation of human meibomian gland function


Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a pld-inducing compound, such as the cationic amphiphilic drugs (e.g. Azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, igf-1 or an igf-1 analogue (e.g.
The Schepens Eye Research Institute




Popular terms: [SEARCH]

Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.1692

5390

1 - 1 - 102